Trial Profile
A randomized, parallel group, multi-centre phase-2 study of GX-G3 compared with pegfilgrastim as an adjunct to chemotherapy in patients with Non-Hodgkin's Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Jun 2019
Price :
$35
*
At a glance
- Drugs Granulocyte macrophage colony stimulating factor (Primary) ; Pegfilgrastim
- Indications Neutropenia
- Focus Therapeutic Use
- Sponsors Ilkogen
- 31 May 2019 Results published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
- 04 Dec 2018 Status changed from recruiting to completed.
- 02 Mar 2016 Status changed from planning to recruiting, according to European Clinical Trials Database record.